Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 206

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment

Open access
Liaw, Yun‐Fan · 2009 · Liver International

Abstract

Chronic hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, the hepatocytes and the immune system of the patient. Perinatally or early childhood‐acquired chronic HBV infection has a long ‘immune tolerant phase’, when patients are young, and HBeAg seropositive with a high viral load but with no significant liver disease. Persistent or episodic liver injuries during the ‘immune clearance phase’ may lead to decompensation, fibrosis progression or cirrhosis development in some patients, but may eventually lead to HBV‐DNA seroclearance with HBeAg seroconversion and entry into the ‘inactive phase’ with remission. Hepatitis may relapse, because of reactivation of HBV with precore or basal core promptor mutations, and develop ‘HBeAg‐negative chronic hepatitis’, in some patients. In contrast, HBsAg seroclearance may occur in those with sustained remission. During the course, HBV replication is the key driver of disease progression including development of cirrhosis and hepatocellular carcinoma (HCC). Among the currently available anti‐HBV drugs, the most extensive and longest experience has been gained with conventional interferon (IFN)‐α and lamivudine. A finite course of IFN therapy has long‐term benefit in achieving a cumulative response, increasing HBsAg seroclearance and reducing cirrhosis and/or HCC. Maintained virological response to lamivudine therapy has a similar long‐term benefit in reducing disease progression. Pegylated IFN and newer nucleos(t)ide analogues may have even better long‐term outcomes because of better therapeutic efficacy and/or a low risk of drug resistances. The treatment outcomes are still far from satisfactory. The development of safe and affordable anti‐HBV agents/strategies is needed to further improve outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2008.01941.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 206

Metadata

Authors
Liaw, Y.
Venue
Liver International
Publisher
Wiley
Published
2009-01
Volume
29
Issue
s1
Pages
100-107
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W1979722884
Cited by
206
References
1
FWCI
10.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment. https://app.cochat.ai/papers/10.1111/j.1478-3231.2008.01941.x
The paper
Liaw, Y. (2009). Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment. Liver International. https://doi.org/10.1111/j.1478-3231.2008.01941.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.